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The major vault protein (MVP) mediates diverse cellular responses,
including cancer cell resistance to chemotherapy and protection
against inflammatory responses to Pseudomonas aeruginosa.
Here, we report the use of photoactive probes to identify MVP
as a target of the N-(3-oxo-dodecanoyl) homoserine lactone
(C12), a quorum sensing signal of certain proteobacteria including
P. aeruginosa. A treatment of normal and cancer cells with C12 or
other N-acyl homoserine lactones (AHLs) results in rapid transloca-
tion of MVP into lipid raft (LR) membrane fractions. Like AHLs,
inflammatory stimuli also induce LR-localization of MVP, but the
C12 stimulation reprograms (functionalizes) bioactivity of the
plasma membrane by recruiting death receptors, their apoptotic
adaptors, and caspase-8 into LR. These functionalized membranes
control AHL-induced signaling processes, in that MVP adjusts the
protein kinase p38 pathway to attenuate programmed cell death.
Since MVP is the structural core of large particles termed vaults,
our findings suggest a mechanism in which MVP vaults act as sen-
tinels that fine-tune inflammation-activated processes such as ap-
optotic signaling mediated by immunosurveillance cytokines
including tumor necrosis factor-related apoptosis inducing ligand
(TRAIL).
bacterial signaling | immunoediting | cross-kingdom communication |
immunosurveillance
Cancer immunoediting is a dynamic process composed ofthree phases—elimination, equilibrium, and escape (1, 2).
According to this hypothesis, if immunosurveillance effectors fail
to mediate apoptosis in nascent neoplasm, the transformed cells
enter the equilibrium phase where they are either maintained
chronically or “edited” immunologically, thereby producing new
populations of tumor variants in the escape phase (2). The in-
flammatory microenvironment—including microbial metabolites
such as lipopolysaccharides (LPS) and proinflammatory cyto-
kines such as tumor necrosis factor (TNF)—affects signaling
processes in cells experiencing any of the three phases of cancer
immunoediting (2–6) and can promote the generation of tumor
cells that are resistant to proapoptotic immunosurveillance fac-
tors, such as TNF-related apoptosis inducing ligand (TRAIL)
(7–9). Of note, the resistance of tumor cells to TRAIL-induced
apoptosis is overcome in the presence of Gram-negative bacte-
ria, which produce N-acyl homoserine lactones (AHLs), such as
C12 (10). The ability of AHLs to affect proapoptotic signaling in
normal and transformed cells (10, 11) suggests a mechanism by
which immunoediting processes are reprogramed in response to
proteobacterial metabolites.
Results and Discussion
Previously, we developed a series of bifunctional photoactive
probes of C12 for chemoproteomic profiling (SI Appendix, Fig.
S1, compounds 6, 7, and 8), of which P6 demonstrated agonistic
characteristics equal to C12 in normal human bronchial epithe-
lial (NHBE) cells (12). To identify C12-specific targets in hu-
man cells, we performed stable isotope labeling by amino acids
(SILAC) experiments on NHBE cells treated with P6 or control
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compounds (vehicle or C12), and after covalent labeling by ul-
traviolet (UV)-irradiation, followed by lysis, orthogonal conjugation
with biotin azide, and affinity purification, the obtained proteome
samples were analyzed by liquid chromatography tandem mass
spectrometry (Fig. 1A). Among several P6-targeted proteins
identified in these studies, the major vault protein (MVP)
Fig. 1. Chemical proteomic analysis identifies MVP as a potential target of C12. (A) General scheme of the chemical proteomics strategy, utilizing the probe
P6 (Left, Bottom). (B) Representative LC–MS profiles of identified MVP peptides. SILAC ratios and peptide sequences are shown on the top. (C) Representative
example of a competition effect of C12 on P6-mediated MVP labeling. Labeling by the probe in the presence of the native molecule C12 (red) is reduced when
compared to labeling with the probe alone (blue). (D) The left panel shows barrel-like structure of vault, with MVP unit marked in green; top and bottom
arrows mark vault cap and shoulder regions, respectively. The right panel shows the results of in silico docking simulation of MVP-C12 interaction, suggesting
C12 (white) localization in a close proximity to shoulder region of vault (yellow). (E) Representative example using the hydrazine (N2H4) cleavable levulinic
linker for the identification of P6 peptide adducts from a vault labeling experiment. The m/z values for matched pair of light (14N) and heavy (15N) adducts
identifying MVP peptide are shown, resulting in a characteristic doublet signal. Images and molecules shown in A, D, and E are not drawn to scale. For
additional information relevant to experiments described above, see SI Appendix, Figs. S2–S4.
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Fig. 2. C12-producing P. aeruginosa and C12 alone induce MVP translocation to LR fractions. (A) Comparison of NHBE cell responsiveness to P. aeruginosa
wild type (wt) or lasI mutant (ΔlasI) by using WB analysis of cellular fractions containing cytosol (C) or LRs for expression of MVP, vimentin (a marker of LR
fractions), and HSP70 (a marker of cytosol fraction). (B) NHBE cells were stimulated with C12 or its unnatural R-stereoisomer (C12R), and cellular samples were
analyzed as in A as well as for expression of PARP4. (C, D) A549 lung cancer cell line (C) and normal human CBM (D) were stimulated with C12 and analyzed as
indicated in B. For additional information relevant to experiments described above, see SI Appendix, Figs. S5 and S6.
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consistently displayed high labeling ratios in comparison to con-
trols (Fig. 1 B and C and SI Appendix, Fig. S2; all proteins that
were identified using this methodology are listed in Dataset S1).
The evolutionarily conserved protein MVP is expressed as
large, barrel-like particles termed vaults that are found in eu-
karyotes, including human cells (Fig. 1D) (13–16). Heterologous
expression of MVP results in an assembly of vault particles,
which are structurally indistinguishable from their naturally oc-
curring counterparts (16–18). Therefore, in order to validate our
cell-based proteomic findings, we examined whether our C12-
based probe P6 targets recombinant human vaults. As expected,
P6 labeled the recombinant vaults in a dose-dependent manner
(SI Appendix, Fig. S3A). Importantly, P6 labeling of MVP was
notably reduced in the presence of C12 (SI Appendix, Fig. S3B),
indicating that both compounds interact with the vault in a similar
manner. To further confirm these findings, the recombinant vault
P6 adducts were additionally coupled with a biotinylated azide
containing a levulinic acid-based cleavable linker. After
streptavidin-based affinity purification, the P6-labeled pep-
tides were released by cleaving the linker using an equimolar
mixture of 15N- and 14N-hydrazine, yielding a characteristic
doublet profile observed in subsequent mass spectrometry analysis
(Fig. 1E). According to the vault crystal structure (19), the identi-
fied P6 peptide adducts (SI Appendix, Fig. S4) were mapped within
the shoulder (residues 445 to 461) and cap (residues 724 to 734)
region of MVP, in agreement with our in silico docking simulation
of the C12 vault complex (Fig. 1D, a panel on the right). Inter-
estingly, these results suggest C12 localization near MVP domains
that could also be involved in interactions with lipid rafts (LRs)
(16, 19).
Previous studies on human airway epithelial cells revealed that
MVP is recruited to LRs in response to Pseudomonas aeruginosa,
and activation of the MVP translocation appears to depend on
the integrity of LPS, although a role of other bacterial metabo-
lites in this cellular process remains unclear (20). To assess
whether C12 is also required for the induction of LR-localized
MVP (rMVP), we compared the subcellular localization of MVP
in NHBE cells treated with wild-type P. aeruginosa or an isogenic
mutant strain lacking lasI, the gene responsible for the synthesis
of C12 (21). A strong and rapid increase in rMVP was evident in
response to wild-type bacteria; however, we found a substantial
reduction in rMVP when cells were treated with C12-deficient
bacteria (Fig. 2A). Of note, the residual levels of rMVP observed
in response to C12-deficient P. aeruginosa could be due to ac-
tivities of other bacterial stimuli, such as LPS (20) or its essential
core component, Kdo2-lipid A (KLA) (SI Appendix, Fig. S5).
To clarify the specific role for C12 in MVP recruitment into
LR fractions, we examined induction of rMVP in NHBE cells
treated with the natural S- or unnatural R-stereoisomer of C12
(SI Appendix, Fig. S6 A and B). The subcellular localization of
the poly(ADP ribose) polymerase type 4 (PARP4), a component
of vaults (22), was also tested. Similar patterns of LR localization
were observed for both components of vaults in response to C12
with natural stereochemistry, whereas the unnatural enantiomer
was completely inactive (Fig. 2B). The induction of LR-localized
vault components was not limited to NHBE cells but was also
observed in the human lung cancer cell line A549 (Fig. 2C) and
normal human cord blood-derived macrophages (Fig. 2D)
treated with C12. The lipophilicity of C12 and other long chain
AHLs allows for direct interaction with the plasma membrane
(23, 24), and thus, the observed recruitment of the vault com-
ponents into lipid-rich membrane rafts in response to AHLs (SI
Appendix, Fig. S6 C–E) is consistent with the hypothesis that
mammalian sensing of AHLs occurs within a membrane-located
system (23).
Observations that C12 activates apoptotic signaling in various
cell types and that MVP modulates cancer cell resistance to
proapoptotic anticancer agents (13, 25) prompted us to investigate
biochemical features relevant to apoptotic effects of C12 and its
ability to induce rMVP in lung cancer cell line A549. Western blot
(WB) analysis revealed that C12-induced activation of apoptotic
caspases and the recruitment of vault components into a LR
fraction occurred with similar kinetics; notably, only caspase-8
(casp8) was translocated into LR fractions in response to C12
(Fig. 3A), strictly resembling the previously reported process ac-
tivation of this initiator caspase in cancer cells responding to
TRAIL (26). Interestingly, the recruitment of casp8 into LR
fractions was equally induced by C12 in both wild-type and MVP-
deficient bone marrow-derived macrophages (BMDM) (Fig. 3B),
suggesting that the observed translocation of vault components
and casp8 are two independent events mediated in response to
the AHL.
To elucidate whether MVP is involved in the regulation of
C12-induced apoptotic signaling, we used cells from wild-type
and MVP knockout mice. Titration experiments showed that
the viability of BMDM as well as mouse embryonic fibroblasts
(MEF) derived from MVP-deficient mice was substantially re-
duced in the presence of C12 when compared to their wild-type
counterparts (SI Appendix, Fig. S7A), suggesting that MVP
contributes to protection against C12-induced cell death. We
also observed that the cleavage of poly(ADP ribose) polymerase
(PARP) and the activation of caspase-3, two indicative features
of apoptosis (27), were faster and more robust in MVP-deficient
cells of both types when compared to their wild-type counter-
parts (Fig. 3 C and D and SI Appendix, Fig. S7B). The MVP
dependency of C12-mediated responses was specific to apoptotic
signaling because the phosphorylation of the eukaryotic trans-
lation initiation factor 2 alpha (p-eIF2α) and the splicing of XbpI
messenger RNA (mRNA), indicative markers of the adaptive
endoplasmic reticulum (ER) stress pathway, displayed similar
patterns in C12-activated, MVP-deficient, and wild-type cells
(Fig. 3 C and D and SI Appendix, Fig. S7C).
Apoptosis is initiated through two distinct signaling pathways:
the intrinsic pathway, triggered by the effector caspase-9 (casp9),
and the extrinsic pathway, that relies on the effector casp8 (27).
Although C12 activates both effector caspases (Fig. 3A), ques-
tions concerning the MVP dependency of this response still
needed to be addressed to explain the observed differences in
the sensitivity of MVP-deficient and wild-type cells to C12. We
found that MVP deficiency substantially increased C12-induced
activity of casp8, whereas the induction of casp9 was indepen-
dent of MVP (Fig. 3 E and F). Other AHLs revealed similar
MVP dependency in activation of apoptotic signaling (SI Ap-
pendix, Fig. S8A). In additional experiments, inflammatory stimuli,
such as LPS and KLA, were also tested as controls. Consistent with
the ability of both inflammatory stimuli to induce antiapoptotic
responses via activation of the NF-κB pathway (6, 9), LPS as well
as KLA did not induce apoptotic signaling in either wild-type or
MVP-deficient cells (SI Appendix, Fig. S8B). Thus, this set of
findings suggests an essential role for a vault in protection against
C12-induced apoptosis exerted through a casp8-dependent mech-
anism. It also may explain chemoresistance associated with MVP
up-regulation in cancer cells (13, 25).
Like LPS, C12 activates the p38 protein kinase pathway that
negatively regulates apoptosis in LPS-activated cells (28). How-
ever, while LPS also induces inflammatory responses in macro-
phages through the activation of NF-κB signaling (6), C12 does
not. Instead, C12 manifests TLR4-independent anti-inflammatory
activity through the inhibition of LPS-mediated transcriptional
induction of NF-κB target genes encoding TNF and other in-
flammatory modulators (11). We found that MVP deficiency had
no effect on the induction of TNF and interleukin-1beta (IL-1β)
expression in LPS-activated macrophages (Fig. 4A, lines in which
cells were treated with LPS alone). Additionally, MVP appears
dispensable for the anti-inflammatory activity of C12, as LPS-
induced TNF production was strongly and equally inhibited by
Rayo et al. PNAS | 3 of 10













































C12 in both wild-type and MVP-deficient BMDM (Fig. 4 A and
B). However, while inflammatory stimuli such as LPS and TNF
induced comparable profiles of p38 phosphorylation (p-p38) in
wild-type and MVP-deficient cells (SI Appendix, Fig. S9), C12-
induced p-p38 was substantially impaired in MVP-deficient
BMDM and MEF (Fig. 4C). In contrast, the C12-mediated ef-
fect on the phosphorylation status of other MAPKs, such as JNK
and ERK, was similar in wild-type and MVP-deficient macro-
phages (see WB results for p-JNK and p-ERK1/2 on Fig. 4C).
Currently, it is unclear whether MVP is directly involved in C12-
induced p38 activation or whether MVP/vault, acting as a trans-
porter of signaling components (29, 30), affects expression of p38
within intracellular compartments. Interestingly, WB analysis for
p38 and JNK expression in cytoplasmic and LR fractions revealed
that cytoplasmic expression of both proteins was unaffected in
MVP-deficient macrophages; however, whereas expression of
JNK was limited to cytoplasm, p38 was also detected in LR
fractions, and levels of the LR-expressed p38 were substantially
reduced in MVP-deficient cells (Fig. 4D). We also noticed a
similarity in responses of MVP- and p38-deficient cells to C12-
induced apoptotic signaling (Fig. 4 E and F; see also SI Appendix,
Fig. S10), suggesting a role for the MVP-p38 axis in cell survival,
for example, in macrophages activated by stimuli other than C12
or a combination of different ones (30, 31).
Integrity of either NF-κB or p38 signaling pathways is essential
for macrophage protection against pathogen- or inflammatory
stimulus-induced apoptosis (28, 32, 33). In TLR4-activated mu-
rine macrophages, proapoptotic immunosurveillance signaling is
mitigated by the survival activity of the IKKβ-NF-κB module and
p38-mediated phosphorylation-dependent activation of the tran-
scription factor CREB (33). Observations that CREB phosphor-
ylation is seen upon C12 addition to TLR4 ligand-pretreated
macrophages (34) prompted us to examine whether C12 alone
could activate CREB in human cord blood-derived macrophages
(CBM). We observed that C12 induced strong phosphorylation
of CREB, which was coincided with activation of p38 but im-
paired when CBM were pretreated with small interfering RNA
(siRNA)-targeting MVP (Fig. 4G); also, the reduction of MVP
expression compromised CBM survival (Fig. 4 G, Bottom). It
could be relevant to previously reported observations that the
MVP-p38 axis is involved in the macrophage scavenger receptor
1 (MSR1)-mediated production of the immunosurveillance cy-
tokine TNF and regulation of apoptotic signaling in macrophage-
like cell line RAW264.7 activated by fucoidan, a ligand of
MSR1 (29).
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Fig. 3. MVP attenuates C12-induced apoptotic signaling. (A) A549 cells were stimulated with C12, and the subcellular fractions were prepared and analyzed
by WB for expression of vault components, apoptotic caspases, and loading control markers as indicated. (B) BMDM from wild-type (MVP+/+) and MVP-
deficient (MVP−/−) mice were treated with C12 as indicated, and the subcellular fractions (cytosolic [C] and LR) were analyzed by WB for expression of casp8,
vault components (MVP and PARP4), and vimentin. (C, D) WB analysis monitoring PARP and casp3 cleavage as well as the phosphorylation of eIF2α (p-eIF2α) in
extracts from wild-type and MVP-deficient MEF (C) or BMDM (D) stimulated with C12 as indicated. (E) Profiles of casp8, casp9, or casp3 activity in BMDM
treated with C12. (F) WB analysis monitoring activation of initiator caspases (casp8 and casp9) in extracts from MVP+/+ or MVP−/− BMDM treated with C12 as
indicated. For additional information relevant to experiments described above, see SI Appendix, Figs. S7 and S8.
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Death receptors, such as TNF receptor type 1 (TNFR1) and
TRAIL receptor type 2 (also called DR5), regulate immuno-
surveillance processes through ligand-induced activation of ap-
optosis in nascent cancer cells (2–9). Since interaction of C12
with the plasma membrane (23, 24) results in TNF-independent
activation of TNFR1-mediated apoptotic signaling (24), we ex-
amined the subcellular localization of TNFR1, TRADD (TNF
receptor-associated death domain), DR5, the apoptotic adaptor
protein FADD, caspase-8, and the vault components in CBM
simulated by C12 or TNF. In keeping in mind that MSR1 has
been identified as a binding partner for MVP (29), analyzing the
localization of MSR1 was also included in these studies. WB
analysis of subcellular fractions from C12- or TNF-stimulated
cells revealed that both stimuli-induced rapid recruitment of
vault components (MVP and PARP4) and MSR1 into LR
fractions (Fig. 5A). We also found that although low levels of
LR-localized TNFR1 and DR5 were detected in response to
TNF, C12 treatment substantially increased recruitment of both
death receptors into LR fractions, in which the presence of
TRADD, FADD, and caspase-8 was also evident (Fig. 5B). In-
terestingly, the similarity between patterns of DR5 and MSR1
localization in cytoplasmic fractions was reproducibly observed
at late time points after C12 stimulation (Fig. 5 A and B), which
could be relevant to C12-induced ER stress response (35) and
TRAIL-independent, DR5-mediated apoptosis (36).
C12 is exclusively produced in certain Gram-negative bacteria
that also possess LPS as a key effector of inflammatory and
immunosurveillance macrophage responses. Therefore, we ex-
amined a subcellular localization of MSR1, vault components,
and death receptor signaling partners in LPS-simulated CBM.
The results of this analysis shown in Fig. 5C revealed that vault
components (MVP and PARP4) and MSR1 were rapidly recruited
into LR in response to LPS, whereas the localization of casp8,
death receptors (DR5 and TNFR1), and FADD was unaffected
and consistent with LPS-induced endogenous expression of TNF
proteins (TNF p26 and TNF p17); changes in a pattern of TNFR1
expression were coincided with TRADD recruitment into mem-
brane fractions. Thus, like C12 or TNF, cells respond to LPS with
translocation of vault components and MSR1 into LR fractions,
indicating that the LR-recruitment of MVP-MSR1 composites is a
consequence of common processes triggered within the plasma
membrane in response to these obviously distinct stimuli.
Within the plasma membrane, LRs are an assemblage of choles-
terol, sphingolipids, and proteins, which can be coalesced—by lipid-
and/or protein-mediated signaling, such as lipid content/structure
alteration, multivalent ligand binding, or protein oligomerization—to
raft platforms that are bioactive in cell membrane functions (37). For
example, a conversion of sphingomyelin (SM) to ceramide (Cer)
triggered in response to inflammatory mediators, such as LPS, and
immunosurveillance cytokines, such as TNF and TRAIL, results in
formation of Cer-rich raft platforms that regulate anti- and
proapoptotic cellular processes essential for cell growth and death
(38–42). Of note, Cer induces cell death (43), but it can also be
hydrolyzed to fatty acid and sphingosine (Sph), and then, through
the sphingolipid salvage pathway (42), acylation of Sph recycles
Cer that further can be metabolized to SM; thus, the restored
homeostatic balance of lipids within the plasma membrane ac-
companied with the antiapoptotic effect of NF-κB signaling pro-
motes survival of LPS- or TNF-activated cells (42, 44). On the
other hand, C12 inhibits TNF-mediated activation of NF-κB sig-
naling (34) but activates apoptosis through TNFR1 oligomeriza-
tion (24) and coincided with recruitment of TNFR1/DR5, its
apoptotic adaptors, and casp8 into LRs (Fig. 5B). These findings
suggest that lipophilic interaction of C12 with the plasma mem-
brane promotes Cer-rich raft platform formation, but similar in-
teraction with the ER membrane, where de novo synthesis of Cer
A B C
GFED
Fig. 4. MVP deficiency selectively affects C12-induced prosurvival activity of p38 signaling. (A) WB analysis monitoring expression of TNF and interleukin 1
beta (IL-1β) in extracts from wild-type (WT) and MVP-deficient BMDM stimulated with LPS in the presence of indicated doses of C12. (B) TNF secretion from
WT or MVP-deficient (MVP ko) BMDM stimulated with LPS in the presence of indicated doses of C12. (C) WB analysis for p38, eIF2α, JNK, ERK1/2, and their
phosphorylated form as well as MVP in extracts from WT and MVP-deficient BMDM stimulated with C12 as indicated. (D) Three independent cytosol and LR
fractions from WT (1 to 3) or MVP-deficient BMDM (ko; 4 to 6) were analyzed for expression of p38, JNK, and loading control (vim, an abbreviation for
vimentin). (E) WB analysis of PARP, p-p38, p-eIF2α, and actin in cellular extracts from WT and p38-deficient cells stimulated by C12. (F) Comparison of casp8
activity in WT and MVP- or p38-deficient cells stimulated with C12 (10 mM) as indicated. (G) After transfection with MVP-specific siRNA (MVP) or nontargeting
control siRNA (NT), untransfected (control) and siRNA-transfected human CBM were treated with C12 for indicated times, and cellular extracts were analyzed
by WB for MVP, p-p38, p-CREB, p-eIF2α, and actin. The same set of CBM were also incubated with C12 for 24 h, and cell viability was measured and shown (the
bottom boxes; three biological replicates) as a percentage of viable (100%) untreated cells.
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Fig. 5. MVP recruitment into LR platforms could regulate immunoediting and immunosurveillance processes. (A) WB analysis monitors expression of the
vault components (MVP and PARP4), MSR1, and vimentin in subfractions from CBM stimulated by C12 or TNF as indicated. (B) Subtractions shown in A were
additionally analyzed for expression of the indicated proteins. (C) Subfractions (C [cytosol], M [membrane], and LR) were prepared from LPS-stimulated CBM
and analyzed for expression of the indicated proteins. (D) Relative levels of radioactivity incorporated into sphingomyelin (SM) after 3H-Sph metabolic la-
beling macrophages treated for different period of time with natural (C12S) or unnatural (C12R) enantiomers of C12; the samples from untreated cells were
used as a control. For additional information, please see SI Appendix, Fig. S9. (E and F) CBM were stimulated with S- or R-enantiomers of C12, and the
prepared subfractions (at 30 min after stimulation) were analyzed for expression indicated on a panel of proteins (E); in parallel, total cellular extracts were
analyzed for expression of the phosphorylated forms of p38 or eIF2α and actin as a loading control (F). (G) After transfection by MVP-specific siRNA (MVP) or a
nontargeting control siRNA (NT), A549 cells treated with C12 (5 μM), TRAIL (10 ng/mL), or a combination of both stimuli for 3 h and cellular extracts were
analyzed by WB for PARP and casp8 cleavage as well as for a full length of casp8 and actin as indicated. Silencing of MVP expression in these cells was also
verified by WB for MVP (insert on the bottom). (H) The same set of A549 transfected cells were incubated with or without C12 (5 μM) in the presence of
indicated doses of TRAIL for 18 h, and cell survival was assessed.
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occurs (45), could affect the sphingolipid salvage pathway. Al-
though further investigations are required to define mechanisms,
our 3H-Sph metabolic labeling experiments on macrophages
revealed that addition of C12 substantially impaired 3H-Sph in-
corporation into Cer and especially SM (Fig. 5D and SI Appendix,
Fig. S11 A–C). These findings suggest that C12 interactions with
the plasma membrane disrupt metabolically balanced sphingolipid
compositions that elicit activation of protein-mediated signaling.
Notably, the natural stereochemistry of C12 is required for the
modulation of sphingolipid metabolism (SI Appendix, Fig. S11B)
and recruitment of protein-contained apoptotic machinery of
death receptors and casp8 into LR platforms as well as for C12-
induced activation of p38 and ER stress-mediated phosphoryla-
tion of eIF2α (Fig. 5 E and F). Importantly, consistent with our
earlier observations on NHBE cells, the translocation of vault
components (MVP and PARP4) into LR fractions was also in-
duced in CBM stimulated only by the natural S-enantiomer of C12
(SI Appendix, Fig. S11D), further supporting specific recognition
of C12 by MVP vaults.
The elevated MVP expression in cancer cells correlates with
resistance to anticancer therapeutic treatments (30, 46), suggest-
ing a role for the vaults in immunoediting/immunosurveillance
processes. Of note, lung cancer A549 cells express high levels of
MVP (46) and show resistance to apoptosis induced by the
immunosurveillance cytokine TRAIL (7), but C12 restores the
sensitivity of tumor cells to TRAIL (10). This effect of C12 on
TRAIL activity against cancer cells could be relevant to disruption
of sphingolipid metabolism because the apoptotic response to
TRAIL+C12 was blocked by D-MAPP, an inhibitor of Cer me-
tabolism (47), whereas bortezomib-mediated effect on TRAIL-
induced apoptosis was unaffected by D-MAPP (SI Appendix,
Fig. S11E); also, D-MAPP blocked C12-induced signaling,
whereas responses to LPS were unaffected (SI Appendix, Fig.
S11 F and G). Having identified the MVP vault as an anti-
apoptotic effector of C12, we examined whether MVP is involved
in A549 cell resistance to TRAIL. As expected, apoptotic signaling
in control siRNA-transfected A549 cells was slightly increased in
response to a combination of TRAIL and C12, whereas siRNA-
mediated reduction of MVP expression resulted in substantial
enhancement of apoptotic signaling (Fig. 5G). Titration experi-
ments confirmed that MVP-specific siRNA-targeted cells were
more sensitive to TRAIL (Fig. 5H). Thus, the observed MVP
involvement in TRAIL-induced apoptosis in lung cancer cells may
indeed regulate cancer immunoediting/immunosurveillance pro-
cesses, especially upon P. aeruginosa infections.
Our findings suggest a specific function for MVP vaults in the
recognition of C12 and other AHLs as indicative signals for the
presence of AHL-producing proteobacteria, such as P. aerugi-
nosa. Through acting in concert with a TLR4-dependent re-
sponse to LPS (3, 6, 9, 28), vaults could contribute to survival of
activated cells, thereby coupling processes of host immuno-
surveillance (2, 9, 10) (SI Appendix, Fig. S11C) and pathogen
elimination (20, 48) with resolution of cellular responses to
classical inflammatory stimuli including TNF. Therefore, further
investigation is warranted into the structure–activity relationships
between components of vaults for their therapeutic potential
against inflammation-mediated pathologies, including cancer.
Methods
General Methods and Reagents. All chemical reagents for organic synthesis
were purchased from Sigma-Aldrich or Acros (Thermo Fisher Scientific) and
used without further purification. Solvents were dried with an MBraun
solvent purification system. Reactions were monitored by thin-layer chro-
matography (TLC) using commercially available glass plates precoated with
silica (0.25 mm, Merck 60 F254), which were developed using potassium
permanganate. Flash chromatography was performed on Merck 40 to 63 μm
silica gel. NMR analyses were performed using a Bruker Avance DPX400
or DMX500. Spectra were calibrated on residual solvent signal. All AHLs,
including C12 and C12R, were synthesized following published procedures
(49–51). The synthesis of P6 was previously described (52). The purity of all
compounds’ purity was confirmed by liquid chromatography–mass spec-
troscopy (LC–MS) and NMR analysis. In addition, a quantitative QCL-1000
Chromogenic Limulus Amoebocyte Lysate Assay (BioWhittaker, Inc.)
demonstrated that preparations of C12 and other AHLs were endotoxin
free. [3-3H]-D-erythro-sphingosine (20 Ci/mmol) was obtained from Amer-
ican Radiolabeled Chemicals, Inc. Sphingolipids (Cer, Sph, SP1, DMS, and
other lipids) were obtained from Matreaya. In general, synthetic molecules
were dissolved in dimethyl sulfoxide (DMSO) or ethanol at 200× of the
desired concentration, and aliquots were stored at −20 °C. LPS (Escherichia coli
serotype 055:B5) was purchased from Sigma-Aldrich while Salmonella minnesota
Re595 LPS was prepared as previously described (53). The core structural
component of LPS, also referred to Di[3-deoxy-D-manno-octulosonyl]-lipid
A, Kdo2-Lipid A, or KLA, was obtained from Avanti. Supernatant levels of
TNF or IL-6 in the samples were measured by enzyme-linked immunosorbent
assay (BD Biosciences Pharmingen).
Live-Cell Labeling with Diazirine Analog Probes. Cells were plated at 20%
confluence in culture medium and grown to approximately 90% confluency.
Stock solutions of the probes and the C12 were dissolved in DMSO. Medium
was replaced 12 h prior to the experiment. Compounds were added to a
concentration indicated in figure legends, and the cells were incubated for
30 min. The cells were washed once with cold phosphate-buffered saline
(PBS) and UV irradiated for 15 min on a UV table at 365 nm at 4 °C. Cells
were collected using a cell scraper, and stored at −80 °C. For SILAC experi-
ments, labeling was performed in a similar manner, but the cells were grown
in SILAC Dulbecco’s Modified Eagle Medium (DMEM) and dialyzed fetal
bovine serum (FBS) purchased from Biological Industries complemented with
isotopically enriched arginine and lysine for the heavy medium, or with the
same light amino acids, all purchased from Sigma-Aldrich.
CuAAC Chemistry for In-Gel Visualization. CuAAC chemistry was performed
based on protocols from the Cravatt Laboratory (54). The protein concen-
tration of each sample was measured using a bicinchoninic acid BCA protein
assay (Pierce BCA Protein Assay Kit; Thermo Fisher Scientific) and normalized
by dilution with PBS to approximately 1 to 3 mg/mL. For each sample, 1 mL
proteome was taken, and the following reagents were added: rhodamine
azide (10 μL 10 mM in DMSO, final concentration: 100 μM); tris(2-carbox-
yethyl)phosphine (TCEP; 20 μL 50 mM in PBS, prepared fresh, final concen-
tration: 1 mM); tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (60 μL 1.7 mM
in 1:4 DMSO:t-butanol, final concentration: 100 μM); CuSO4 (20 μL 50 mM in
double-distilled water [DDW], final concentration: 2 mM). The mixture was
allowed to react for 1 h at room temperature on a shaker. Lastly, the samples
were analyzed by sodium dodecyl sulfate (SDS)-polyacrylamide gel electro-
phoresis gel, and the gel was visualized using an ImageQuant LAS 4000 Imager
(Fujifilm) set in Cy3 fluorescence mode (excitation/emission = 520 nm/575 nm).
CuAAC Protocol and Sample Preparation for Proteomics Analysis. Sample
preparation was performed based on protocols from the Cravatt Laboratory
(54). For SILAC samples, the heavy and light proteomes were combined in a
1:1 ratio before proceeding. CuAAC chemistry was performed as described
above, using biotin azide instead of rhodamine azide. Excess reagents were
removed using methanol/chloroform (MeOH/CHCl3) precipitation: the sam-
ples were transferred to 15 mL conical tubes on ice, 2 mL cold MeOH was
added, 0.5 mL cold CHCl3 was added, and the sample was vortexed. Next,
1.0 mL cold PBS was added and the sample was vortexed and centrifuged at
5,000 rpm for 10 min. The top and bottom layers were removed, leaving the
protein interface, and the sample was washed with 1:1 MeOH:CHCl3 (1.0 mL,
3×). 2 mL of MeOH was added and the sample was sonicated with a probe
sonicator, and then 0.5 mL CHCl3 was added. Lastly, the sample was
centrifuged at 5,000 rpm for 10 min to pellet protein and the supernatant
was removed. Next, the samples were denatured and reduced: 500 μL 6M
urea (in PBS, made fresh) and 50 μL premixed 100 mM TCEP/300 mM K2CO3
solution (in PBS) were added and the sample was sonicated and incubated
for 30 min at 37 °C in shaker. Next, 70 μL 400 mM iodoacetic acid was added
and incubated for 30 min at room temperature in the dark, 140 μL 10% SDS
in PBS was added, and the sample was diluted with 5.5 mL PBS.
Enrichment and Trypsinization for Proteomics Analysis. Enrichment and tryp-
sinization was performed based on protocols from the Cravatt Laboratory
(54). Enrichment was performed as follows: Sample was added to 100 μL of
Streptavidin beads (beads were washed 3× with 500 μL PBS) and incubated
1.5 h at room temperature on shaker. The sample was centrifuged to pellet
beads, and the beads were washed 3×, each of 10 mL 0.2% SDS/PBS, PBS,
and DDW. Lastly, the beads were transferred to low-binding Eppendorf
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tubes using 2× 0.5 mL DDW and spun down, and then the supernatant was
removed. Trypsinization was performed as follows. The following reagents
were premixed and then added to each tube: 200 μL 2M urea/PBS, 2 μL
100 mM CaCl2, and 4 μL Trypsin (20 μg reconstituted in 40 μL Trypsin buffer).
The tubes were shaken overnight (up to 12 h) at 37 °C. The beads were then
pelleted by a brief centrifugation, and the supernatant and beads were
transferred to a small spin column, and the supernatant was collected by
centrifugation. The beads were washed with 100 μL PBS and collected in the
same tube. The filtrate was acidified using 16 μL formic acid and stored
at −20 °C.
Proteomics MS Analysis. Samples were analyzed using an LTQOrbitrap XL ETD
(Thermo Fisher Scientific) coupled to a NanoLC-2D (Eksigent), and proteins
were identified with ProLuCID (55), using parameters as previously reported
(56). SILAC ratio was calculated using CImage (57). Full SILAC results are
available in the MassIVE database under accession number MSV000084474
(https://doi.org/doi:10.25345/C5P95Q) (58).
Labeling of Purified Vaults. Purified human recombinant vaults were prepared
following previously reported procedures (18). For labeling experiments,
1 μM vaults were incubated with varying concentrations of P6 (1, 5, or
10 μM) with or without C12 (1 to 100 μM) for half an hour on a shaker.
Labeling, CuAAC chemistry, and in-gel visualization were performed as
described above.
Docking Studies. C12 structure extracted from the Protein Data Bank (PDB)
3IX3 was docked onto an MVP chain from the vault crystal structure (PDB
4v60) with a blind docking method using Binding Site Prediction with Shape-
based LIgand Matching (BSP-SLIM) (https://zhanglab.ccmb.med.umich.edu/
BSP-SLIM/) (59). Data were analyzed and figures were generated using
PyMOL.
Cleavable Levulinic Linker Synthesis. The linker was synthesized according to
the scheme shown in SI Appendix, Fig. S12. First, 4-oxonon-8-ynoic acid was
synthesized as previously reported (52). To a solution of 4-oxonon-8-ynoic
acid (504 mg, 3 mmol) and 1,2-bis(2-azidoethoxy) (6 g, 10 eq., 30 mmol) in
dimethylformamide (DMF):H2O (9:1, 30 mL), CuCl (94 mg, 0.2 eq., 0.6 mmol)
and sodium ascorbate (178 mg, 10.3 eq., 0.9 mmol) were added, and the
mixture was stirred overnight at room temperature. The mixture was filtered
through a short pad of celite and was used without further purification. The
crude acid, biotin-ethanolamine (862mg, 3 mmol), N-hydroxysuccinimide (345mg,
3 mmol), and 4-dimethylaminopyridine (36 mg, 0.3 mmol) were dissolved in DMF
(30 mL). The carbodiimide 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (747
mg, 3.9 mmol) was added portion wise, and the mixture was stirred for 14 h.
Finally, it was concentrated under reduced pressure, and the title compound was
obtained after reversed-phase high-performance liquid chromatography purifi-
cation (10% → 90% MeCN/0.1% TFA).
NMR spectra are shown in SI Appendix, Fig. S13; 1H NMR (400 MHz,
DMSO): δ 1.21 to 1.40 (m, 2H), 1.40 to 1.69 (m, 4H), 1.79 (quint., J = 7.4 Hz,
2H), 2.07 (t, J = 7.3 Hz, 2H), 2.54 to 2.63 (m, 3H), 2.69 (t, J = 6.4 Hz, 2H), 2.82
(dd, J = 5 Hz, 12.4 Hz, 1H), 3.06 to 3.13 (m, 1H), 3.26 (quad, J = 5.5 Hz, 2H),
3.37 (m, 3H), 3.52 to 3.58 (m, 6H), 3.81 (t, J = 5 Hz, 3H), 3.98 (t, J = 5.6 Hz, 2H),
4.13 (m, 1H), 4.31 (m, 1H), 4.47 (t, J = 5 Hz, 2H), 6.42 (s, 1H), 6.36 (s, 1H), 7.82
(s, 1H), and 7.09 (t, J = 5.5 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ 23.6, 24.8,
25.6, 28, 28.5, 28.6, 35.5, 37, 37.9, 41.5, 49.7, 50.4, 55.8, 59.6, 61.5, 63.1, 69.2,
69.6, 70, 70, 122.7, 146.7, 163.2, 172.7, 172.8, and 209.1.
Cleavable Levulinic Linker Model Cleavage Reaction. To verify that this labeling
method is feasible, the cleavable levulinic linker was incubated overnight
with 50 mM of heavy (15N) and light (14N) hydrazine at pH 7.5, and the re-
action was analyzed by LC–MS. Only two major products were detected:
dihydropyridazin-3-one and biotin aminoethanol. The desired dihydropyr-
idazin-3-one showed the expected doublet profile for the heavy and light
cleavage showing incorporation of two 15N atoms into the product, with
peaks detected at 365.31 m/z and 367.28 m/z (predicted mass + H: 365.19
and 367.19 m/z for heavy and light, respectively).
MS Analysis of Purified Vaults. The CuAAC reactions were performed as above
for biotinylation of 1 μM purified vaults using a cleavable levulinic linker
(100 μM). The enrichment and trypsin digest were performed as described
above, without the chloroform/methanol precipitation steps. Data analysis
was performed as detailed above, and then the labeled peptides were
identified using a custom Python script, which searched for heavy and light
labeled peptides of a similar intensity (at least 80% similarity) within 2-min
retention time windows. The script is available at https://github.com/
barashe/levulinic_linker (60).
Mice, BMDM, and Other Cells. C57BL/6 mice were purchased from the Jackson
Laboratory. MVP-deficient mice and littermate controls (all mice were of the
C57BL/6 background) were described previously (61). BMDM and MEF were
prepared by using standard protocols. MEFs deficient in p38α were obtained
from p38α loxp/loxp mice and immortalized with a retrovirus expressing the
large T antigen. The p38α loxp/loxp mice were kindly provided by Huiping
Jiang, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT. NHBE were
obtained from Cambrex and cultured as recommended by the manufacturer.
Lung cancer epithelial cell line A549 was purchased from the American Type
Culture Collection (ATCC). Normal human CD34+ cord blood cells obtained
from StemCell Technologies were cultured as recommended by the manu-
facturer and used for preparation of normal human CBM as previously de-
scribed (62). MEF and cell lines were maintained in the following growth
medium (GM): DMEM (4.5 g/L glucose) supplemented with 10% FBS (HyClone
Laboratories, Inc.), L-glutamine, penicillin/streptomycin, and nonessential
amino acids (Invitrogen). BMDM were cultured in 70% GM and 30% L929
conditioned medium. In general, cells (∼60 to 70% confluence) were incu-
bated in corresponding fresh medium for 12 to 14 h before stimulation.
Exposure of NHBE Cells to Bacteria. The P. aeruginosa bacteria used in our
studies were kindly provided by Scott A. Beatson, University of Queensland,
Brisbane, Australia, and include wild-type P. aeruginosa PAO1 (originally
from ATCC) and PAO1 ΔlasI. The bacteria were grown on brain heart infu-
sion (BHI) agar plates and then transferred to inoculum culture overnight,
followed by 1/100 dilution into 20 mL BHI broth in 125 mL baffled shake
flasks for incubation at 37 °C, 250 rpm for 4 to 6 h. The equal aliquots of the
late log phase culture or control BHI broth were transferred to PVDF inserts,
which were placed in 24-well plates containing target cells cultured in 0.5 mL
GM as previously described (34).
Determination of C12 Concentration in Bacterial Cultures. A total of 2 mL
bacterial culture was acidified with 50 μL HCl and 10 mL ethyl acetate was
added, and the contents were mixed vigorously. The layers were allowed to
separate, and 5 mL of the ethyl acetate layer were removed, dried over
MgSO4, and concentrated in vacuo. The residue was resuspended in cold
methanol and centrifuged to remove the precipitate. The resulting metha-
nol solution was analyzed by LC–MS for C12 content. Reverse phase LC–MS
analysis (Agilent ZORBAX column, 5 μm, 300SB-C8, 4.6 × 50 mm) was per-
formed with gradients of MeCN–H2O–0.1% formic acid (from 0 to 1 min: 5%
MeCN, from 1 min to 9 min: gradient of 5%MeCN to 98%MeCN, and from 9
to 11 min: 98% MeCN), allowing for quantification of C12 by measuring the
following ions: 298 (M + H+), 316 (M + H2O + H
+), 320 (M + Na+), and 338
(M + H2O + Na
+). The concentration of C12 in the samples of P. aeruginosa
PAO1 (wild type) was about 4.3 μM (P < 0.001, n = 5 independent experi-
ments). Similar samples from LasI-deficient bacteria as well as from Staph-
ylococcus aureus and Salmonella typhimurium were C12-negative.
Antibodies and WB Analysis. Antibodies specific for vimentin, HSP70, the full-
length caspase-3 (casp3FL), the cleaved form of caspase-3 (casp3cleaved), the
full-length caspase-8 (casp8FL), the cleaved form of caspase-8 (casp8cleaved),
the full-length caspase-9 (casp9), eIF2α, phospho-eIF2α (p-eIF2α), p38, phospho-
p38 (p-p38), MKK3/MKK6, phospo-MKK3, and PARP were purchased from Cell
Signaling; anti-actin antibodies were from Sigma; and anti-MVP antibodies and
anti-PARP4 were from GeneTex. The cellular extracts were prepared and ana-
lyzed by WB as previously described (63).
Cell Stimulation. In all experiments, cells were stimulated with C12 (in a range
of 2 to 20 μM), LPS (100 ng/mL), or their combination as indicated in the
figure legends; MEF were stimulated with TNF (40 ng/mL) or KLA (50 nM) as
indicated in text or figure legends. CBM were stimulated with 10 nM of KLA.
Subcellular Fractionation. ProteoExtract Subcellular Proteome Extraction Kit
(Calbiochem, category no. 539790) was used for the differential extraction of
proteins according to their subcellular localization. All subcellular fraction-
ation experiments were performed as recommended by the manufacturer.
XBP1 Assay. The XBP1 splicing assay for expression of uXBP1 or sXBP1 mRNA
was done by using the OneStep RT-PCR Kit from QIAGEN. Primers encompassing
the spliced sequences in XPB1 mRNA (mouse: 5′-GGCCTTGTGGTTGAGAACCAG-
GAG-3′, 5′-GAATGCCCAAAAGGATATCAGACTC-3′; human: 5′- GAACCAGGA-
GTTAAGACAGC-3′, 5′-AGTCAATACCGCCAGAATCC-3′) were used for RT-
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PCR amplification, and products were separated by electrophoresis through
5% polyacrylamide gel on tris-borate or tris-acetate-EDTA buffer and visu-
alized by ethidium bromide staining.
Cell Viability. Since prolonged incubation of cells with high concentration of
C12 (50 μM or higher) exerts a cytotoxic effect (35), in our studies we used
low concentration of C12 (from 5 to 25 μM for macrophages and 10 to 40 μM
for fibroblast and epithelial cells), and the duration of all experiments was
limited up to 3 h. Under these conditions, the viability of C12-treated cells
was indistinguishable from control cells, as was determined by using an XTT-
based Toxicology Assay Kit (Sigma).
Metabolism of [3H]-Sphingosine in Macrophages. Metabolic labeling and
analysis of sphingosine metabolism was performed according to the method
described by Yatomi et al. (64) with modifications. BMDM were set up in
30 mm dishes (∼105 cells per dish) and cultured for 2 d. The cells were in-
cubated with 25 nM [3H]-sphingosine (1 μCi) in the presence or absence of
20 μM C12. At the indicated times, the dish was put on ice and washed by
cold PBS, and the cells were collected by centrifugation, resuspended in
0.2 mL of ice-cold PBS, and 1.875 mL of mixture containing chloroform/
methanol/concentrated HCl (100:200:1) was added. The lipids were extracted
from the cell suspensions by the method of Bligh and Dyer (65). The lipids
were recovered in a small volume of chloroform/methanol (2:1); the aliquots
(about 5,000 cpm per each sample) of lipid fractions were applied to silica
gel 60 TLC plates (Merck), and the plates were developed in butanol/acetic
acid/water (3:1:1). The appropriate lipid standards were run on the same TLC
plate. The bands were identified by staining the control lipids with primulin
and following visualization under UV light. After enhancer (EN3HANCE
spray, PerkinElmer Life & Analytical Sciences) treatment of the TLC plate,
autoradiography was performed with Kodak MS film at −80 °C for 20 to
40 h. In some experiments, the radioactive spots were scraped off and
counted by liquid scintillation counting. Each autoradiograph shown is
representative of at least three experiments.
Caspase Assay. The activity of caspase-3, caspase-8, and caspase-9 were
measured by using caspase assay kits (R&D System) as recommended in
manufacturer’s protocols.
Statistics. Data depicted in Figs. 1–4 and SI Appendix, Figs. S1–S11 represent
one of three or more experiments with each graph reflecting findings typical
of multiple studies, and the data were expressed as the relative fold in-
creases compared to the values of untreated or control-treated cells (n = 3
to 5).
Data Availability. Full proteomics and SILAC results are available in the
MassIVE database under accession number MSV000084474 (58). Python script
for the peptide labeling strategy using the levulinic acid linker is available on
Github: https://github.com/barashe/levulinic_linker (60).
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